# A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension

> **NCT06212752** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 39 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Nab-paclitaxel
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Filgrastim
- **DRUG:** Pegylated filgrastim

## Key facts

- **NCT ID:** NCT06212752
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-13
- **Primary completion:** 2024-11-06
- **Final completion:** 2028-05-22
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2025-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06212752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06212752, "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06212752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*